New Test Helps Diagnose MS Faster and Accurately Today

Credibility

Interest

Share:2 min read

Key Takeaway

A simple lab measure called the KFLC index in spinal fluid helps diagnose MS nearly as well as the standard test and also relates to how active the disease is.

What They Found

Researchers tested the KFLC index, which measures tiny immune proteins called kappa free light chains (KFLC) in spinal fluid and blood, in 262 people. MS patients had much higher KFLC index numbers than people with other or no inflammatory brain diseases, showing the test picks up MS-related immune activity. A cutoff number near 6 (they found 5.48 was optimal, and 6.1 worked well) separated most people with MS from those without it. The KFLC index worked about as well as the current lab test called oligoclonal bands (OCB), which looks for specific immune proteins only in spinal fluid. Higher KFLC index values were seen when MS was active and when MRI scans showed more brain lesions, suggesting the test also links to disease activity.

Who Should Care and Why

People with MS and caregivers should care because KFLC testing could make diagnosis easier and faster, like using a new reliable thermometer to check a fever. Doctors and nurses should care because it gives another clear lab result to use alongside other tests, especially when results are unclear. This may help patients get diagnosis and treatment decisions sooner, which can reduce delays in starting therapies. Caregivers can use this information to ask about KFLC testing if lumbar puncture (spinal tap) samples are taken, much like asking for an extra blood test when two labs can help a diagnosis. Neurologists might still use the older OCB test in some cases, so KFLC adds value rather than fully replacing current practice.

Important Considerations

This study looked back at stored samples from one French center, so results might differ in other hospitals or regions. The KFLC cutoff of about 6 worked well overall but may be less accurate in men, so doctors may combine tests for the best answer. Also, while KFLC links to disease activity, this does not prove it predicts future attacks or long-term outcomes without more studies.

AI-generated summary — for informational purposes only, not medical advice

Categories:

MS Diagnostics Clinical Trials Early Research

Article Topics:

KFLC indexKappa free light chainMultiple sclerosisOligoclonal bands

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Journal of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News